🇺🇸 FDA
Patent

US 10023637

Combination immunotherapy for the treatment of cancer

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 10023637 (Combination immunotherapy for the treatment of cancer) held by The Board of Regents of the University of Texas System expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K38/1709, A61K39/3955